Next Article in Journal
Improving Hepatocellular Carcinoma Surveillance Outcomes in Patients with Cirrhosis after Hepatitis C Cure: A Modelling Study
Previous Article in Journal
High-Dose-Rate Brachytherapy for Treatment of Facial Skin Cancers: Local Control, Toxicity, and Quality of Life in 67 Patients
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Tasci et al. RadWise: A Rank-Based Hybrid Feature Weighting and Selection Method for Proteomic Categorization of Chemoirradiation in Patients with Glioblastoma. Cancers 2023, 15, 2672

Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD 20892, USA
*
Author to whom correspondence should be addressed.
Cancers 2024, 16(15), 2744; https://doi.org/10.3390/cancers16152744
Submission received: 14 May 2024 / Accepted: 10 June 2024 / Published: 1 August 2024
In the original publication [1], there was a mistake shown in Tables 1–8 and Figures 3–5 and 7 as published. The pre/post-categorization information of four patients in our proteomic dataset was incorrectly labeled, requiring the proteomic analysis to be repeated. We repeated our analyses depending on the newly constructed, corrected, and normalized dataset. The newly obtained results are given in the corrected Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7 and Table 8 and Figure 3, Figure 4 and Figure 5 and Figure 7 below.
References
59.
Zeng, S.; Li, W.; Ouyang, H.; Xie, Y.; Feng, X.; Huang, L. A Novel Prognostic Pyroptosis-Related Gene Signature Correlates to Oxidative Stress and Immune-Related Features in Gliomas. Oxid. Med. Cell. Longev. 2023, 2023, 4256116. https://doi.org/10.1155/2023/4256116.
The repeat analysis has resulted in superior results as compared to the previous analysis with the best ACC% now 96.364, which was obtained with the Logistic Regression Model, and the minimum weight of 10. The selected number of features is now 8. Best Feature (Biomarker) Set is as follows: ‘K2C5’, ‘MIC-1’, ‘CSPG3’, ‘GFAP’, ‘STRATIFIN’, ‘Cystatin M’, ‘Keratin-1’ and ‘Proteinase-3’. All places in the manuscript text where the new results have resulted in a numerical change e.g., ACC, AUC, have been corrected to reflect the new findings in the updated tables. With this correction, the order of some references has been adjusted accordingly. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Tasci, E.; Jagasia, S.; Zhuge, Y.; Sproull, M.; Cooley Zgela, T.; Mackey, M.; Camphausen, K.; Krauze, A.V. RadWise: A Rank-Based Hybrid Feature Weighting and Selection Method for Proteomic Categorization of Chemoirradiation in Patients with Glioblastoma. Cancers 2023, 15, 2672. [Google Scholar] [CrossRef] [PubMed]
Figure 3. The visualization of the effects of the feature selection procedures with accuracy (ACC%) determined by a supervised learning method in conjunction with the feature selection approach (mRMR FS (yellow), LASSO FS (blue), and no FS (green)).
Figure 3. The visualization of the effects of the feature selection procedures with accuracy (ACC%) determined by a supervised learning method in conjunction with the feature selection approach (mRMR FS (yellow), LASSO FS (blue), and no FS (green)).
Cancers 16 02744 g003
Figure 4. The effects of the number of features related to the minimum weight value using LASSO and mRMR-based feature selection with weighting methods.
Figure 4. The effects of the number of features related to the minimum weight value using LASSO and mRMR-based feature selection with weighting methods.
Cancers 16 02744 g004
Figure 5. Mean accuracy rate (ACC) vs. minimum weight stratified by model employed in analysis.
Figure 5. Mean accuracy rate (ACC) vs. minimum weight stratified by model employed in analysis.
Cancers 16 02744 g005
Figure 7. Ingenuity pathway analysis (IPA) carried out on April 5, 2023, illustrating linkage of the identified protein features to the top 2 upstream mediators (Supplementary Data Table S2). (A) Epidermal growth factor (EGF) (p-value of overlap 2.53 × 10−7). (B) Catenin beta 1 (CTNNB1) (p-value of overlap 2.41 × 10−6). (C) IPA-generated merged network for the 8 ML-identified proteins using the disease classification brain cancer.
Figure 7. Ingenuity pathway analysis (IPA) carried out on April 5, 2023, illustrating linkage of the identified protein features to the top 2 upstream mediators (Supplementary Data Table S2). (A) Epidermal growth factor (EGF) (p-value of overlap 2.53 × 10−7). (B) Catenin beta 1 (CTNNB1) (p-value of overlap 2.41 × 10−6). (C) IPA-generated merged network for the 8 ML-identified proteins using the disease classification brain cancer.
Cancers 16 02744 g007
Table 1. Accuracy rates: Five supervised learning models with or without feature selection. Color changes from red to green display performance results from the lowest (red) to the highest values (green).
Table 1. Accuracy rates: Five supervised learning models with or without feature selection. Color changes from red to green display performance results from the lowest (red) to the highest values (green).
ML-ACCWithout FSLASSO FSmRMR FS
SVM57.86078.67491.515
LR67.63385.34192.708
KNN62.19753.06888.466
RF73.82688.46689.659
AdaBoost88.40989.07288.447
Table 2. Performance results (i.e., ACC%) using only LASSO-based feature selection and weighting methods. Color changes from red to green display performance results from the lowest (red) to the highest values (green). The bold value indicates the best result.
Table 2. Performance results (i.e., ACC%) using only LASSO-based feature selection and weighting methods. Color changes from red to green display performance results from the lowest (red) to the highest values (green). The bold value indicates the best result.
k# of FeaturesSVMLRKNNRFAdaBoost
51193.31492.08382.38691.49691.477
42689.64093.31462.19793.93990.890
34489.05396.36346.34592.12193.939
29085.98592.06460.37991.49693.901
119776.26985.96654.86887.84187.822
Table 3. Performance results (i.e., ACC%) using only mRMR-based feature selection and weighting methods. Color changes from red to green display performance results from the lowest (red) to the highest (green) values. The bold value indicates the best result.
Table 3. Performance results (i.e., ACC%) using only mRMR-based feature selection and weighting methods. Color changes from red to green display performance results from the lowest (red) to the highest (green) values. The bold value indicates the best result.
k# of FeaturesSVMLRKNNRFAdaBoost
5586.00488.42887.23587.84187.197
4790.89092.70890.26591.49691.496
3895.15296.36492.70890.87193.920
21192.70896.36492.68990.28494.508
13492.10292.10287.25492.12190.871
Table 4. Mean performance results (i.e., ACC %, CV = 5) determined using both LASSO and mRMR-based feature selection with weighting methods. Color changes from red to green display performance results from the lowest (red) to the highest values (green). The bold value indicates the best result.
Table 4. Mean performance results (i.e., ACC %, CV = 5) determined using both LASSO and mRMR-based feature selection with weighting methods. Color changes from red to green display performance results from the lowest (red) to the highest values (green). The bold value indicates the best result.
k# of FeaturesSVMLRKNNRFAdaBoost
15287.21687.21689.65987.84185.379
14287.21687.21689.65987.84185.379
13490.26590.26590.28492.72789.034
12693.92092.70891.47792.10293.314
11693.92092.70891.47792.10293.314
10895.15296.36492.70890.26593.920
9895.15296.36492.70890.26593.920
8895.15296.36492.70890.26593.920
71093.33394.54690.28492.10290.284
61293.93995.15290.90991.49690.246
51796.34595.11488.44791.49690.871
43293.29595.73968.92190.89089.640
35292.12195.15149.96293.33392.670
211387.21692.67060.37991.49695.152
121878.08785.96655.49289.05393.314
Table 5. The standard deviation of performance results (i.e., ACC %, CV = 5) determined using both LASSO and mRMR-based feature selection with weighting methods. Color changes from red to green display performance results from the lowest (red) to the highest values (green).
Table 5. The standard deviation of performance results (i.e., ACC %, CV = 5) determined using both LASSO and mRMR-based feature selection with weighting methods. Color changes from red to green display performance results from the lowest (red) to the highest values (green).
k# of FeaturesSVMLRKNNRFAdaBoost
1525.1754.4084.0724.2322.191
1425.1754.4084.0724.2322.191
1344.4234.8214.4254.9242.384
1265.0605.2693.5094.0883.515
1165.0605.2693.5094.0883.515
1083.6364.4545.2693.4964.272
983.6364.4545.2693.4964.272
883.6364.4545.2693.4964.272
7104.8485.5554.4254.0884.425
6124.2853.6366.3573.9953.526
5172.9662.4443.4764.8275.400
4326.1774.1056.3844.2591.442
3524.5352.4247.3294.0202.469
21134.8071.5574.9544.4304.924
12184.7203.1335.5593.0313.515
Table 6. Performance results without employing feature selection and feature weighting. Color changes from red to green display performance results from the lowest (red) to the highest values (green).
Table 6. Performance results without employing feature selection and feature weighting. Color changes from red to green display performance results from the lowest (red) to the highest values (green).
MLACC%AUCF1PRERECSPEC
SVM57.8600.4150.5180.6980.5150.690
LR67.6330.7550.6760.6810.6810.673
KNN62.1970.6470.5810.6620.5270.722
RF73.8260.8080.7440.7680.7460.737
AdaBoost88.4090.9510.8860.8820.8930.873
Table 7. Performance results employing LASSO and mRMR-based feature selection with weighting operation. Color changes from red to green display performance results from the lowest (red) to the highest values (green).
Table 7. Performance results employing LASSO and mRMR-based feature selection with weighting operation. Color changes from red to green display performance results from the lowest (red) to the highest values (green).
MLACC%AUCF1PRERECSPEC
SVM95.1520.9890.9490.9750.9280.976
LR96.3640.9870.9640.9630.9650.965
KNN92.7080.9650.9300.9290.9320.923
RF90.2650.9780.9020.8850.9280.876
AdaBoost93.9200.9790.9410.9410.9420.935
The best ACC% is 96.364, which was obtained with the Logistic Regression Model, and the minimum weight is 10. Selected Number of Features: 8. Best Feature (Biomarker) Set is as follows: ‘K2C5’, ‘MIC-1’, ‘CSPG3’, ‘GFAP’, ‘Proteinase-3’, ‘STRATIFIN’, ‘Cystatin M’, and ‘Keratin-1’ [59].
Table 8. Overview of the identified proteomic biomarkers illustrating the biological relevance to glioma.
Table 8. Overview of the identified proteomic biomarkers illustrating the biological relevance to glioma.
Entrez Gene SymbolTarget Full NameBiological Relevance to Glioma
K2C5Keratin, type II cytoskeletal 5Yes, evolving biomarker/target [61]
Keratin-1Keratin, type II cytoskeletal 1Yes, evolving biomarker/target [61]
STRATIFIN
(SFN)
14-3-3 protein sigmaYes, tumor suppressor gene expression pattern correlates with glioma grade and prognosis [62]
MIC-1 (GDF15)Growth/differentiation factor 15Yes, biomarker, novel immune checkpoint [63]
GFAPGlial fibrillary acidic proteinYes, evolving biomarker/target [64]
CSPG3 (NCAN)Neurocan core proteinYes, glycoproteomic profiles of GBM subtypes, differential expression versus control tissue [65]
Cystatin M (CST6)Cystatin MYes, cell type-specific expression in normal brain and epigenetic silencing in glioma [66]
Proteinase-3
(PRTN3)
Proteinase-3Yes, evolving role, may relate to pyroptosis, oxidative stress and immune response [59]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Tasci, E.; Jagasia, S.; Zhuge, Y.; Sproull, M.; Cooley Zgela, T.; Mackey, M.; Camphausen, K.; Krauze, A.V. Correction: Tasci et al. RadWise: A Rank-Based Hybrid Feature Weighting and Selection Method for Proteomic Categorization of Chemoirradiation in Patients with Glioblastoma. Cancers 2023, 15, 2672. Cancers 2024, 16, 2744. https://doi.org/10.3390/cancers16152744

AMA Style

Tasci E, Jagasia S, Zhuge Y, Sproull M, Cooley Zgela T, Mackey M, Camphausen K, Krauze AV. Correction: Tasci et al. RadWise: A Rank-Based Hybrid Feature Weighting and Selection Method for Proteomic Categorization of Chemoirradiation in Patients with Glioblastoma. Cancers 2023, 15, 2672. Cancers. 2024; 16(15):2744. https://doi.org/10.3390/cancers16152744

Chicago/Turabian Style

Tasci, Erdal, Sarisha Jagasia, Ying Zhuge, Mary Sproull, Theresa Cooley Zgela, Megan Mackey, Kevin Camphausen, and Andra Valentina Krauze. 2024. "Correction: Tasci et al. RadWise: A Rank-Based Hybrid Feature Weighting and Selection Method for Proteomic Categorization of Chemoirradiation in Patients with Glioblastoma. Cancers 2023, 15, 2672" Cancers 16, no. 15: 2744. https://doi.org/10.3390/cancers16152744

APA Style

Tasci, E., Jagasia, S., Zhuge, Y., Sproull, M., Cooley Zgela, T., Mackey, M., Camphausen, K., & Krauze, A. V. (2024). Correction: Tasci et al. RadWise: A Rank-Based Hybrid Feature Weighting and Selection Method for Proteomic Categorization of Chemoirradiation in Patients with Glioblastoma. Cancers 2023, 15, 2672. Cancers, 16(15), 2744. https://doi.org/10.3390/cancers16152744

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop